Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy.
Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41.3% vs 13.0%; P<0.001). On the multivariate Cox analyses, preoperative International Index of Erectile Function-5 scores (hazard ratio (HR), 1.049; P=0.040), alcohol consumption (HR, 2.043; P=0.020) and Gleason biopsy score (HR, 0.368; P=0.024) were independent preoperative predictors for potency recovery. Among post-RP variables, the use of robotic procedures (HR, 2.287; P=0.030) and pathologic stage (HR, 0.506; P=0.038) were significantly associated with potency recovery. This study identified predictive factors for the recovery of potency in patients undergoing penile rehabilitation with udenafil following RP. Our results could provide physicians with useful information for counseling RP patients and selecting optimal candidates for penile rehabilitation.
Department of Urology, School of Medicine, Kyungpook National University, Daegu, South Korea.
T-H
TH
Kim
Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea.
Y-S
YS
Ha
Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea.
S H
SH
Choi
Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea.
E S
ES
Yoo
Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea.
B W
BW
Kim
Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
S-J
SJ
Yun
Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea.
W-J
WJ
Kim
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Y S
YS
Kwon
Department of Urology, School of Medicine, Chilgok Kyungpook National University, Daegu, South Korea.
T G
TG
Kwon
D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000534:rehabilitation; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage; D011183:Postoperative Complications / Q000188:drug therapy / Q000503:physiopathology / Q000534:rehabilitation; D011379:Prognosis; D011468:Prostatectomy / Q000009:adverse effects* / Q000379:methods; D011471:Prostatic Neoplasms / Q000601:surgery; D011743:Pyrimidines / Q000008:administration & dosage*; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D056910:Republic of Korea; D012307:Risk Factors; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome; D000096926:Benzenesulfonamides
D058986:Phosphodiesterase 5 Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C419664:udenafil; D000096926:Benzenesulfonamides